Currently, China's herpes zoster vaccine industry is thriving under the promotion of health awareness and policy guidance. This article is based onMoxie ConsultingLatest Release"Analysis Report on China's Herpes Zoster Vaccine Industry"Analyze the competitive landscape of China's herpes zoster vaccine industry, outlining the R&D product pipelines, technological innovations, and key competitive factors such as corporate competition.
Competitive Landscape of the Shingles Vaccine Market:Led by GSK, the rise of Chinese production shows a favorable competitive landscape.Four Shingles Vaccines Have Been Launched Globally, Two of Which Have Been Approved in China. To date, four shingles vaccines have been launched globally, respectively.Merck & Co.TheZostavax、GSKTheShingrix、SK Chemicals Co., Ltd.TheSkyZosterAndBcht BiotechnologyTheGanwei. Among themZostavaxDue to its lower protective efficacy, it was discontinued in the United States in November 2020. In China, two vaccines have been launched, respectively.GSKTheShingrixAndBcht BiotechnologyTheSenseVital。
Screenshot source: MosaEntropy Consulting's "Analysis Report on China's Herpes Zoster Vaccine Industry," data sourced from MosaEntropy Pharma China's Market Approval Database, other publicly available information, etc.The market landscape in China presents a duopoly competition trend, mainly led byGSKTheShingrixAndBcht BiotechnologyTheGanwei VaccineLead.Zhifei BiologicalAndGSKCooperative PromotionShingrix, further driving market penetration. With the intensification of aging and increased public awareness, the market potential is enormous and is expected to continue expanding in the future.Screenshot source: Mosec Consulting's "Analysis Report on China's Herpes Zoster Vaccine Industry," data sourced from Mosec Pharmaceutical Biological Lot Release Database, Changchun Bcht Biotechnology Co.'s official website, and other public channels.Trends in Antigen Technology for Herpes Zoster Vaccines:Recombinant Protein Technology Leads the Way, mRNA Vaccines EmergeIn terms of protection rate,GSKThe protective efficacy of the recombinant protein route exceeds 90%, showing a clear advantage over the attenuated live vaccine technology route; with the development of new mRNA technologies, their application in shingles vaccines is becoming a trend.Source of screenshot: Maxentropy Consulting's "Analysis Report on China's Shingles Vaccine Industry", data sourced from GSK's official website and other public data.Pipeline layout develops rapidly, 19 vaccines enter the review process, Green Bamboo Biotech takes the lead, Maike Kang makes a breakthroughFrom the enterprise perspective,Green Bamboo Biotech'Recombinant Protein VaccineCompleted Phase III clinical trials and applied for marketing, leading the industry;Maikang、Zhonghui Yuantong、RecoBioare in Phase III clinical trials,Sino CellsPhase II clinical trials to be advanced,Yuanda SaiweiEight companies, including Changchun Bcht Biotechnology Co., have initiated Phase I clinical trials.Jia Chen Xi HaiFour companies have applied for clinical trials, forming a multi-level R&D梯队; in terms of technical routes, recombinant proteins account for 57.9%, RNA technology accounts for 31.6%, and attenuated live vaccines account for 10.5%, showing a diversified pattern; in terms of registration categories, Class 1.2 companies focus on the development of new antigens, accounting for 68.4%, while Class 1.3 companies explore new adjuvants, accounting for 21.1%, laying a foundation for future competition through differentiated layouts.'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
![]()
Screenshot source: Mesentropy Consulting's "Analysis Report on China's Herpes Zoster Vaccine Industry," data from Mesentropy Medicine's China Drug Evaluation DatabaseCurrently, China has a rich and diverse pipeline of shingles vaccines under development. Numerous companies are actively engaged in research and development, covering various types of vaccines. Among them,Green Bamboo Biopharmaceutical Co., Ltd.TheRecombinant Zoster Vaccine(CHO cells)Has applied for listing and is expected to achieve a breakthrough first.Shanghai Maikang Biotechnology Co., Ltd.Products from several companies are in Phase III clinical trials, undergoing rigorous verification on key indicators such as vaccine efficacy. Quite a few companies are in Phase I, Phase II clinical trials, or in the process of applying for clinical trials, such asSinovac Life Sciences Co., Ltd.'Lyophilized Herpes Zoster Virus mRNA Vaccine...also emerging, showcasing China's vigorous innovation vitality and diversified development trends in the field of shingles vaccine research and development.![]()
Screenshot source: Mesentropy Consulting's "Analysis Report on China's Herpes Zoster Vaccine Industry," data from Mesentropy Medicine's China Drug Evaluation Database
SWOT Analysis of Herpes Zoster Vaccine:Diversified Competition Landscape for Shingles Vaccines in China: Marketed and Under ResearchGSKUsing recombinant protein technology, it was approved for marketing in 2017, with mature technology and excellent protective effects for the elderly population. It has achieved considerable global sales, with a significant year-on-year increase of 72% in 2022.Changchun Bcht Biotechnology Co.Using attenuated live vaccine technology, it is low-cost, requires fewer doses, suitable for people over 40 years old, was approved for marketing in 2023, and achieved remarkable sales in its first year on the market.Significant progress has been made in the development of vaccines in China.Green Bamboo BiotechTheRecombinant Protein VaccineAlready applied for listing, head-to-head clinical trial data showed excellent performance, expected to be launched as early as the fourth quarter of 2025.Maikang BioNew adjuvant vaccine,Zhonghui Yuantong BiotechnologyAndRecoBioTheRecombinant Protein VaccineBoth are in Phase III clinical trials, and are expected to bring new options to the market and meet the needs of different populations by leveraging their respective technical advantages, such as high immunogenicity and optimized production processes.Screenshot source: Mosec Consulting's "Analysis Report on China's Herpes Zoster Vaccine Industry", data sourced from Mosec Pharma China Drug Evaluation Database, GSK, Changchun Bcht Biotechnology Co., Green Bamboo Biotech, Maikang Bio official websites and other public materials.
InHerpes Zoster VaccineIn the research, development and application in China, adjuvants play an important role, and different types of adjuvants exhibit unique characteristics.Aluminum Salt AdjuvantIt is widely used and adopted by many manufacturers. Its main components are aluminum hydroxide and aluminum phosphate, which have a unique structure capable of adsorbing antigens onto the surface of aluminum salts, thereby activating the Nalp3 inflammasome and effectively inducing humoral immune responses. This adjuvant has the significant advantages of low cost and good safety, but it has certain limitations in inducing cellular immunity.GSKCompany'sAS01B Adjuvant, applied in its recombinant shingles vaccine. The adjuvant contains a liposome matrix and immunostimulatory molecules.(such as QS21)Components such as these can activate dendritic cells, efficiently induce T-cell immune responses, and make the vaccine's protective efficacy as high as 97.16%. However, it should be noted that it may cause adverse reactions such as fever and body pain.BchtTheVaricella Zoster Vaccine Live AttenuatedAn adjuvant-free strategy was adopted, relying on attenuated live vaccine technology to enhance the immune memory of the body.Adjuvants for shingles vaccines under research in China are also showing many highlights.Maikang BiotechnologyTheMA105 Composite AdjuvantSystem, which can activate stronger cellular immunity;Zhonghui YuantongTheAluminum/CpG Composite Adjuvant, showing outstanding performance in inducing humoral and cellular immunity;RecoBioTheBFA01 AdjuvantAndAS01B AdjuvantSimilarly, they possess high protective efficacy. These adjuvants continue to evolve, laying a solid foundation for enhancing the immune response of herpes zoster vaccines.Screenshot source: Mosun Consulting "Analysis Report on China's Shingles Vaccine Industry", data from GSK, Changchun Bcht Biotechnology Co., Lutzhu Biotechnology, Maikang Biotechnology official websites, "Emerging concepts in the science of vaccine adjuvants" and other public materials.Company OverviewGSKSeveral companies have their own advantages in terms of market value, financing, and capital reserves. In terms of sales and products,GSKCompanies with different cooperation models show significant differences in sales promotion and product line layout. Some focus on human vaccines, some venture into pet vaccines, and others have a rich R&D pipeline but need to improve their sales system. In the fields of R&D and production, companies emphasize different technical platforms, and their production base layouts also vary, all providing support for the development of herpes zoster vaccines and other vaccine products.Screenshot source: Mosaix Consulting's "Analysis Report on China's Shingles Vaccine Industry," data sourced from Mosaix Pharma China Drug Approval Database, GSK, Changchun Bcht Biotechnology Co., Luzhu Biotech, Maikang Biotech official websites and other public materials.Driven by Health Needs and Policy Promotion, China's Shingles Vaccine Industry is Booming. The current market is dominated by a duopoly, with great future potential. Technologically, recombinant protein leads the way, while mRNA is emerging, forming a pipeline of 19 vaccines under research. Different companies' products have their own advantages, adjuvant research and development continue to innovate, leading to fierce market competition in the future, which will provide consumers with more high-quality choices.
Copyright Statement: This article is reproduced fromMoxEntropy Pharmaceuticals,Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.
Rooted in Shanghai and radiating globally, PharmaCircle serves as a strategic platform for the biopharmaceuticals industry with the mission of "enabling the borderless flow of intelligence and networks." It builds an empowering system covering the entire pharmaceutical industrial chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource connections, industry think tanks, and ecosystem communities—it establishes the infrastructure for value flow within China's pharmaceutical sector.
Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources—this is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for leapfrog growth of enterprises.
